Tags

Type your tag names separated by a space and hit enter

Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.
Cancer 2015; 121(19):3472-80C

Abstract

BACKGROUND

The incidence of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is higher among African Americans than among other races, but to the authors' knowledge, the characteristics of NLPHL in this population have not been evaluated. The authors compared clinical features, treatments, and survival of black and white patients with NLPHL using the National Cancer Data Base.

METHODS

The authors extracted the records of 602 black and 1950 white patients with NLPHL who were diagnosed between 1998 and 2011. Overall survival (OS) was compared using the log-rank test.

RESULTS

Black patients were on average younger than white patients (median age, 42 years vs 45 years; P =.0001), more often female (49% vs 29%; P<.0001), and more likely to have the axillary lymph nodes as the primary disease site (25% vs 17%; P =.0002). They also had unfavorable socioeconomic characteristics, a higher rate of no treatment in patients with early-stage disease, and a longer time to therapy initiation (median, 53.5 days vs 47 days; P<.0001). Despite this, the authors found no significant difference between the races with regard to stage distribution or survival (P =.39). OS at 7 years was 90.1% in patients with early-stage (American Joint Committee on Cancer stage IA/B, IIA) and 79.4% in patients with advanced stage (American Joint Committee on Cancer stage IIB, III/IV) NLPHL. Survival in the early stage of disease was not found to be significantly different after various treatment strategies (stratified log-rank P = .18), except that the administration of chemotherapy was associated with a better outcome in black patients (log-rank P =.011 vs P =.81 for white patients).

CONCLUSIONS

Differences in clinical presentation suggest the interaction of race-specific and sex-specific susceptibility factors for NLPHL. Further research is needed to elucidate these factors, and to investigate possible heterogeneous effects of treatments by race. Clinical trials comparing standard treatment strategies are unlikely to detect differences in OS among patients with early-stage NLPHL.

Authors+Show Affiliations

Department of Medicine, The Warren Alpert Medical School of Brown University, Providence, Rhode Island. Department of Medicine, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island.Department of Medicine, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island.Division of Hematology-Oncology, Roger Williams Medical Center, Providence, Rhode Island.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26149294

Citation

Olszewski, Adam J., et al. "Race-specific Features and Outcomes of Nodular Lymphocyte-predominant Hodgkin Lymphoma: Analysis of the National Cancer Data Base." Cancer, vol. 121, no. 19, 2015, pp. 3472-80.
Olszewski AJ, Shrestha R, Cook NM. Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base. Cancer. 2015;121(19):3472-80.
Olszewski, A. J., Shrestha, R., & Cook, N. M. (2015). Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base. Cancer, 121(19), pp. 3472-80. doi:10.1002/cncr.29527.
Olszewski AJ, Shrestha R, Cook NM. Race-specific Features and Outcomes of Nodular Lymphocyte-predominant Hodgkin Lymphoma: Analysis of the National Cancer Data Base. Cancer. 2015 Oct 1;121(19):3472-80. PubMed PMID: 26149294.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base. AU - Olszewski,Adam J, AU - Shrestha,Rajesh, AU - Cook,Nathaniel M, Y1 - 2015/07/06/ PY - 2015/01/05/received PY - 2015/03/02/revised PY - 2015/03/20/accepted PY - 2015/7/8/entrez PY - 2015/7/8/pubmed PY - 2016/2/2/medline KW - health care disparities KW - minority health KW - nodular lymphocyte-predominant Hodgkin lymphoma KW - outcomes research SP - 3472 EP - 80 JF - Cancer JO - Cancer VL - 121 IS - 19 N2 - BACKGROUND: The incidence of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is higher among African Americans than among other races, but to the authors' knowledge, the characteristics of NLPHL in this population have not been evaluated. The authors compared clinical features, treatments, and survival of black and white patients with NLPHL using the National Cancer Data Base. METHODS: The authors extracted the records of 602 black and 1950 white patients with NLPHL who were diagnosed between 1998 and 2011. Overall survival (OS) was compared using the log-rank test. RESULTS: Black patients were on average younger than white patients (median age, 42 years vs 45 years; P =.0001), more often female (49% vs 29%; P<.0001), and more likely to have the axillary lymph nodes as the primary disease site (25% vs 17%; P =.0002). They also had unfavorable socioeconomic characteristics, a higher rate of no treatment in patients with early-stage disease, and a longer time to therapy initiation (median, 53.5 days vs 47 days; P<.0001). Despite this, the authors found no significant difference between the races with regard to stage distribution or survival (P =.39). OS at 7 years was 90.1% in patients with early-stage (American Joint Committee on Cancer stage IA/B, IIA) and 79.4% in patients with advanced stage (American Joint Committee on Cancer stage IIB, III/IV) NLPHL. Survival in the early stage of disease was not found to be significantly different after various treatment strategies (stratified log-rank P = .18), except that the administration of chemotherapy was associated with a better outcome in black patients (log-rank P =.011 vs P =.81 for white patients). CONCLUSIONS: Differences in clinical presentation suggest the interaction of race-specific and sex-specific susceptibility factors for NLPHL. Further research is needed to elucidate these factors, and to investigate possible heterogeneous effects of treatments by race. Clinical trials comparing standard treatment strategies are unlikely to detect differences in OS among patients with early-stage NLPHL. SN - 1097-0142 UR - https://www.unboundmedicine.com/medline/citation/26149294/Race_specific_features_and_outcomes_of_nodular_lymphocyte_predominant_Hodgkin_lymphoma:_Analysis_of_the_National_Cancer_Data_Base_ L2 - https://doi.org/10.1002/cncr.29527 DB - PRIME DP - Unbound Medicine ER -